The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedcentric Regulatory News (RCN)

Share Price Information for Redcentric (RCN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 143.00
Bid: 143.00
Ask: 145.00
Change: 0.75 (0.53%)
Spread: 2.00 (1.399%)
Open: 143.00
High: 143.00
Low: 143.00
Prev. Close: 142.25
RCN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on forensic review and remedial action plan

13 Dec 2016 15:07

RNS Number : 7479R
Redcentric PLC
13 December 2016
 

 

13 December 2016

Redcentric plc

("Redcentric" or the "Company")

 

Update on forensic review and remedial action plan

 

Redcentric (AIM:RCN) provides the following update on the progress made with its forensic review previously announced on 7 November 2016.

 

Initial findings from the forensic review 

 

As previously announced, following an internal review by the Company's audit committee in relation to the interim results for the six months ended 30 September 2016, misstated accounting balances in the Group's balance sheet were discovered. Redcentric promptly appointed Deloitte LLP ("Deloitte") and Nabarro LLP ("Nabarro") to carry out an independent forensic review.

 

The forensic review and management's initial findings are as follows.

 

• Net assets impairment: The cumulative overstatement of net assets and profits after tax up to 30 September 2016 is approximately £20.8 million. The current position is that approximately £5.9 million of this misstatement (£4.7 million at the EBITDA level) arose in the six months ended 30 September 2016 and will be reflected in the Company's interim results when they are published this month. The remaining £14.9 million misstatement relates to periods prior to and including the year ended 31 March 2016. To date there has been no evidence of theft and the misstatements are attributable to profit overstatement over a number of years with revenues being overstated and costs understated in broadly equal proportions.

 

• Net debt: As previously reported, the net debt position for both 31 March 2016 and 30 September 2016 is materially higher than originally reported. As at 31 March 2016, net debt was £37.8 million and as at 30 September 2016 net debt was £34.4 million.

 

However, the net debt position as at the period ends mentioned above are not representative because creditors had been significantly stretched at those dates. The average month end net debt position over the past eight months to 30 November 2016 was £42.0 million. This is expected to reduce as billing and debtor collection processes are improved.

 

Banking covenants

  

As noted in the announcement on 7 November 2016, the Company has recalculated its historic banking covenants due to the impact of various accounting adjustments. The Company is pleased to report that it has secured waivers from its Banks in relation to historic covenants such that it is fully compliant with its facilities. The Banks remain supportive of Redcentric and constructive discussions are ongoing in relation to the agreement of future covenant levels which reflect management's business plan.

 

Remedial action plan

 

As well as promptly appointing Deloitte and Nabarro to carry out the independent forensic review, management have also prepared and are executing a remedial plan of action.

 

Some important first steps have been made. These include the appointment of Peter Brotherton as Chief Financial Officer and Julian Llewellyn as Interim CFO. Both are based at Redcentric's headquarters in Harrogate. A full review of the entire finance function is underway, being directly led by Peter Brotherton.

 

A number of initial improvements have already been made including changes to billing and credit control management systems and processes. The restructuring of the finance function will continue as necessary.

 

Interim results announcement and outlook

 

The Company will report its interim results before 31 December 2016.

 

The Company currently expects to report for the six months ended 30 September 2016 revenue of approximately £53.0 million and EBITDA* of approximately £9.1 million. Given the recurrent nature of a majority of the Group's revenue, being in excess of 80% of total Group revenue, the Board believes that this performance is indicative of the performance for the second half of the year. The sales pipeline remains strong at approximately £93.0 million and the H1 sales targets were exceeded, incorporating 38 new client wins.

 

Given the increase in the Company's net debt position, the Board has resolved not to declare an interim dividend. With an anticipated improvement in net debt, the Board will review the Company's dividend policy at the time of the full-year results.

 

The Company has been very encouraged and appreciative of the supportive response from its employees, clients and prospective clients. The Company is focused on completing the matters outstanding in response to the forensic review, reporting the interim results and engaging with our valued clients and staff.

 

This announcement contains inside information.

 

 Enquiries:

 

Redcentric plc

via Tulchan Communications

Fraser Fisher, Chief Executive Officer

 

Peter Brotherton, Chief Financial Officer

 

 

 

Tulchan

+44 (0)20 7353 4200

James Macey White / Matt Low

 

 

 

Numis Securities Limited - Nomad & Joint Broker

+44 (0)20 7260 1000

Simon Willis / Ben Stoop / Oliver Hardy

 

 

 

finnCap Ltd - Joint Broker

+44 (0)20 7220 0500

Stuart Andrews / Rhys Williams

 

 

* Earnings before interest, tax, depreciation, amortisation of acquired intangibles, transaction and integration costs and share based payments.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFIEFELVLIR
Date   Source Headline
28th Aug 20148:48 amRNSHolding(s) in Company
27th Aug 20142:24 pmRNSIssue of Options
26th Aug 201411:48 amRNSHolding(s) in Company
21st Aug 20142:43 pmRNSHolding(s) in Company
21st Aug 20147:00 amRNSDirectorate Change
11th Aug 20144:47 pmRNSHolding(s) in Company
11th Aug 201410:41 amRNSHolding(s) in Company
8th Aug 20142:57 pmRNSResult of AGM
8th Aug 20147:00 amRNSTrading update and AGM statement
7th Jul 20147:00 amRNSChange of Registered Office
4th Jul 20142:54 pmRNSHolding(s) in Company
2nd Jul 20147:00 amRNSIssue of Equity
19th Jun 20144:16 pmRNSDividend Timetable and Notice of AGM
16th Jun 20147:00 amRNSFinal Results
5th Jun 20147:00 amRNSContract Win
15th May 20147:00 amRNSContract Win
30th Apr 20147:00 amRNSContract Wins
2nd Apr 20148:30 amRNSDirectors' Dealings
31st Mar 20147:00 amRNSPre-close Trading Update
28th Mar 20144:37 pmRNSHolding(s) in Company
24th Feb 20147:00 amRNSContract Win
13th Feb 20147:00 amRNSContract Win
5th Feb 20149:19 amRNSIssue of Equity
15th Jan 20147:00 amRNSDirectorate Change
17th Dec 20137:00 amRNSInterim Results
11th Dec 20131:32 pmRNSHolding(s) in Company
9th Dec 20133:45 pmRNSHolding(s) in Company
6th Dec 201311:59 amRNSHolding(s) in Company
5th Dec 201311:23 amRNSHolding(s) in Company
5th Dec 201311:05 amRNSResult of general meeting and re-admission to AIM
21st Nov 20136:12 pmRNSHolding(s) in Company
20th Nov 20135:46 pmRNSHolding(s) in Company
20th Nov 20134:49 pmRNSHolding(s) in Company
19th Nov 20133:50 pmRNSHolding(s) in Company
18th Nov 20131:00 pmRNSSchedule 1 - Redcentric plc
18th Nov 20137:00 amRNSAcquisition of InTechnology, Placing, Re Admission
28th Oct 20137:00 amRNSContract Wins
21st Oct 20137:00 amRNSContract Wins
30th Sep 20137:00 amRNSSupplementary Disclosure
17th Sep 20137:00 amRNSChange of Nominated Adviser
9th Sep 20132:20 pmRNSHolding(s) in Company
5th Jul 20139:25 amRNSHolding(s) in Company
5th Jul 20139:19 amRNSHolding(s) in Company
28th Jun 20137:01 amRNSDirectorate Change
28th Jun 20137:00 amRNSTrading Statement
27th Jun 20137:00 amRNSContract Wins
24th Jun 20137:00 amRNSIssue of Equity
21st May 20137:00 amRNSContract Wins
20th May 201312:17 pmRNSHolding(s) in Company
9th May 20137:00 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.